Speakers

Scott Antonia, Michael Atkins, Edward Garon, David Gerber, Geoffrey Gibney

Scott Antonia, MD, PhD

Chair, Department of Thoracic Oncology
H. Lee Moffitt Cancer Center
Professor of Oncologic Sciences
University of South FL College of Medicine
Tampa, FL

Dr. Antonia is currently the Department Chair of the Thoracic Oncology Department at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. He is also a Professor of Oncologic Sciences at the University of South Florida College of Medicine in Tampa, FL. Prior to being named chair of Thoracic Oncology in 2010, he was associate chairman of the Sarcoma Department. He joined the Moffitt Cancer Center in 1994. Dr. Antonia received his M.D. and his Ph.D. in Immunology from the University of Connecticut Health Center in Farmington, CT. In addition, he completed an internal medicine residency at Yale University School of Medicine in New Haven, CT, and pursued additional training at Yale through a medical oncology fellowship and post-doctoral fellowship in Immunobiology.

Dr. Antonia’s work focuses on translational research. Using his molecular biology and cellular background in the development of immunotherapeutic strategies for the treatment of cancer patients, he has developed strategies designed to thwart the immunosuppressive mechanisms used by tumors to evade T-cell mediated rejection. His clinical interests focus on immunotherapy and immunobiology, in particular, gene-modified tumor cell vaccine trials at both pre-clinical and clinical stages. He has designed and conducted numerous cutting-edge studies with novel immunotherapeutics and has two patents for technology he has developed.

Dr. Antonia has been awarded a K24 grant from the National Cancer Institute to support his clinical research and is the principal investigator for a Thoracic SPORE project. He is also conducting several ongoing investigator-initiated clinical trials testing novel tumor vaccines, and tumor vaccine augmentation strategies for the treatment of various cancers.

Dr. Antonia serves as chairman of Moffitt’s Scientific Review Committee and medical director of the Tumor Vaccine Production Facility at Moffitt. He was named the Moffitt Physician of the Year in 2005 and Mentor of the Year in 2008 and is the recipient of the following distinguished awards: “Top Publication Clinical Science Award” – Moffitt Cancer Center (2016); “W. Jackson Pledger Researcher of the Year Award” – Moffitt Cancer Center (2016); “43rd Annual Jenaro Haddock Memorial Award” – San Juan, PR (2017).

Dr. Antonia has published papers in several peer-reviewed journals, including Science, Clinical Cancer Research, Current Opinions in Oncology, and Cancer Research. In 2014, he was recognized as the “Most Cited Faculty” during the Moffitt Faculty Appreciation/Recognition Reception. In 2015, he was inducted into the National Academy of Inventors.

Back to top

Michael Atkins, MD

Professor of Oncology and Medicine (Hematology/Oncology)
School of Medicine
Georgetown University
Deputy Director
Georgetown-Lombardi Comprehensive Cancer Center
Washington, DC

Dr. Atkins is Deputy Director of the Georgetown-Lombardi Comprehensive Cancer Center and Professor of Oncology and Medicine (Hematology/Oncology) at Georgetown University School of Medicine in Washington, DC. He also leads the Melanoma Disease Group within the Medstar Georgetown Cancer Network and the joint Immunotherapy Initiative between Georgetown-Lombardi and Hackensack University Medical Center.

Prior to his move to Georgetown, Dr. Atkins was Deputy Chief of the Division of Hematology/Oncology, Director of the Cancer Clinical Trials Office, Director of the Cutaneous Oncology Program, and Director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center (BIDMC). In addition, he was the leader of the Kidney Cancer Program at the Dana-Farber/Harvard Cancer Center (DF/HCC) and Professor of Medicine at the Harvard Medical School. He served as Director of the DF/HCC Kidney Cancer Specialized Program of Research Excellence (SPORE) grant and co–principal investigator of the DF/HCC Skin Cancer SPORE since their inceptions in 2003 and 2001, respectively.

Dr. Atkins completed his medical education at Tufts University School of Medicine, and postgraduate training as a resident and chief resident in the Department of Medicine and fellow in the Division of Hematology/Oncology at Tufts New England Medical Center (Tufts-NEMC). He was on staff in the Division of Hematology/Oncology at Tufts-NEMC from 1987 until joining the staff at BIDMC in 1997.

Dr. Atkins’ major research interests are cancer immunotherapy, treatment of melanoma and renal cell carcinoma, predictive markers for response to biologic therapy, and antiangiogenic and targeted therapies. His research work has been funded continuously by the National Cancer Institute, various foundations, and several pharmaceutical companies since 1987.

Dr. Atkins is considered an international authority on melanoma, kidney cancer and cancer immunotherapy. He has been on the editorial boards of several journals, including Cancer, Journal of Translational Medicine, Kidney Cancer Journal, Journal of Clinical Oncology, and is Associate Editor to Journal of Immunotherapy. Dr. Atkins has authored over 350 peer reviewed original research articles, book chapters, review articles and editorials and has edited three books. He also edits the melanoma and kidney cancer sections of UpToDate: a digital medical textbook.

Dr. Atkins serves on the advisory boards of the Melanoma Research Foundation and the Kidney Cancer Association, is a member of the NCI Recombinant DNA Advisory Counsel and the CTEP Immunotherapy Task Force and is past president of the Society for Immunotherapy of Cancer.

Dr. Atkins has disclosed that he is a consultant for Bristol-Myers Squibb, Genentech, Merck, Necktar, Novartis, and Pfizer.

Back to top

Edward Garon, MD, MS

Director, Thoracic Oncology Program
Associate Professor of Medicine
David Geffen School of Medicine
University of California, Los Angeles
Chief, Oncology and Hematology
Los Angeles, CA

Dr. Garon is the Director of the Thoracic Oncology Program and Associate Professor of Medicine at the David Geffen School of Medicine at UCLA in Los Angeles, CA. He received his Medical Degree from Washington University School of Medicine in St. Louis, MO and his Masters of Science in Clinical Research from UCLA.

Dr. Garon’s research includes laboratory and clinical investigation with a focus on identifying biomarkers associated with enhanced likelihood of benefit from novel therapeutics. He has served as a principal investigator of national/international phase I, II and III trials, including trials that have led to regulatory approval of two drugs and a companion diagnostic assay.

Dr. Garon has disclosed that he receives grant/research support from AstraZeneca, Bristol-Myers Squibb, Genentech, Lilly, Merck, Novartis, and Pfizer.

Back to top

David Gerber, MD

Associate Professor of Internal Medicine and Clinical Sciences
Division of Hematology-Oncology
Associate Director for Clinical Research
Co-Leader, Experimental Therapeutics Program
Co-Director, Lung Disease Oriented Team
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, TX

David E. Gerber, MD is an Associate Professor of Internal Medicine and Clinical Sciences within the Hematology-Oncology Division at UT Southwestern Medical Center in Dallas, TX. He received his medical degree from Cornell University Medical College in New York, NY and completed a residency in Internal Medicine at UT Southwestern Medical Center in Dallas, TX. He completed a fellowship in medical oncology at Johns Hopkins University School of Medicine in Baltimore, MD and joined the UT Southwestern faculty in 2007.

Dr. Gerber’s research in lung cancer has generated over 80 peer-reviewed publications. He has also written two books and more than a dozen book chapters on the topic of lung cancer. He has received research grants from the American Cancer Society, the American Society of Clinical Oncology, the Cancer Prevention and Research Institute of Texas, the Department of Defense, and the National Cancer Institute.

Dr. Gerber serves as Associate Director for Clinical Research, Co-Leader of the Experimental Therapeutics Scientific Program, and Co-Director of the Lung Disease Oriented Team within the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern, Dallas, TX. He is an active member of the Eastern Cooperative Oncology Group Thoracic Committee. He also serves on the editorial board of the Journal of Clinical Oncology, as an Associate Scientific Advisor for Science Translational Medicine, and as a grant reviewer for the Department of Defense, the American Cancer Society, and the Conquer Cancer Foundation of the American Society of Clinical Oncology.

Back to top

Geoffrey Gibney, MD

Co-Leader of the Melanoma Disease Group
The Lombardi Comprehensive Cancer Center and MedStar Cancer Network
Washington, DC

Dr. Gibney is a Co-Leader of the Melanoma Disease Group at the Lombardi Comprehensive Cancer Center and MedStar Cancer Network in Washington, DC, and a member of the Developmental Therapeutics (Phase I) program.

Dr. Gibney is board certified in both internal medicine and medical oncology and has expertise in treating patients with advanced melanoma and non-melanoma skin cancers (such as basal cell carcinoma, squamous cell carcinoma and merkel cell carcinoma) as well as renal cell carcinoma. He is well recognized for his melanoma and renal cell carcinoma research.

Dr. Gibney’s past clinical research includes the study of adjuvant anti-PD-1 therapy in patients with high-risk resected melanoma, combination immunotherapies (such as ipilimumab plus the novel IDO1 inhibitor, epacadostat) to enhance the clinical benefit in advanced melanoma patients and combination BRAF targeted therapy to overcome drug resistance. He is currently involved in multiple clinical trials studying new immunotherapy strategies in melanoma and other malignancies and is involved in biomarker development for personalized therapeutic strategies in patients with advanced malignancies.

Back to top